RadiAction Medical, a Tel Aviv, Israel-based developer of an innovative radiation shielding device for fluoroscopic systems in interventional suites, completed a $5.7m in Series A funding.
The round was led by HighGround Tairun Investment LLPs, an investment fund co-managed by HighGround Capital and Boya Capital from China.
The company intends to use the proceeds for accelerating the R&D activity, complete required tests, obtaining regulatory clearances and to get to market with a commercial product.
Founded in 2014 by Dr. Amir Belson, M.D. and Jonathan Yifat (CEO) in the RAD Biomed incubator in Israel, RadiAction has developed technology that involves a device that transfers the radiation shielding from the personnel to the fluoroscopy system itself, while integrating with the physician’s workflow and featuring zero-impact on the X-ray image quality.
The solution will allow medical teams performing image guided interventional procedures to increase the number of procedures performed annually, as well as to extend their stay in the catheterization lab, and reduce the risks involved in exposure to X-ray radiation.
RadiAction’s technology is protected by several patents in the USA and globally.